Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (19365)	4/22/1998 8:07:00 PM
From: WTDEC	Respond to of 32384

"As most readers of this board know, LGND has SERM programs with LLY (Evista), PFE (Droloxifene and CP-366,156), and AHP (TSE424). Moreover, it has its own designer androgen program (LGD1331), which is ready to enter the clinic" Henry, I think the 'Street" must be asleep. I checked all but RS, and none of the analysts have commented on LGND's involvement in these areas recently despite all the public interest in Evista, SERMs, etc. They should wake up as this has the potential to be hugely important (and profitable) for LGND down the road. Regards, W